120 related articles for article (PubMed ID: 21900098)
1. Bevacizumab-induced reversible posterior leukoencephalopathy syndrome and successful retreatment in a patient with glioblastoma.
Lou E; Turner S; Sumrall A; Reardon DA; Desjardins A; Peters KB; Sampson JH; Friedman HS; Vredenburgh JJ
J Clin Oncol; 2011 Oct; 29(28):e739-42. PubMed ID: 21900098
[No Abstract] [Full Text] [Related]
2. Complete remission after bevacizumab plus temozolomide in a patient with recurrent glioblastoma multiforme.
Kilickap S; Oztoprak I; Yucel B
Acta Oncol; 2012 Apr; 51(4):544-6. PubMed ID: 22201408
[No Abstract] [Full Text] [Related]
3. Avastin: more questions than answers. .
Desjardins A; Sampson JH
J Neurosurg; 2012 Feb; 116(2):336-40; discussion 340. PubMed ID: 22035270
[No Abstract] [Full Text] [Related]
4. Neuro-oncology: What is the optimal use of bevacizumab in glioblastoma?
Desjardins A
Nat Rev Neurol; 2015 Aug; 11(8):429-30. PubMed ID: 26195258
[No Abstract] [Full Text] [Related]
5. Addition of lomustine for bevacizumab-refractory recurrent glioblastoma.
Tonder M; Eisele G; Weiss T; Hofer S; Seystahl K; Valavanis A; Stupp R; Weller M; Roth P
Acta Oncol; 2014 Oct; 53(10):1436-40. PubMed ID: 24862539
[No Abstract] [Full Text] [Related]
6. Neoadjuvant bevacizumab and irinotecan versus bevacizumab and temozolomide followed by concomitant chemoradiotherapy in newly diagnosed glioblastoma multiforme: A randomized phase II study.
Hofland KF; Hansen S; Sorensen M; Engelholm S; Schultz HP; Muhic A; Grunnet K; Ask A; Costa JC; Kristiansen C; Thomsen C; Poulsen HS; Lassen U
Acta Oncol; 2014 Jul; 53(7):939-44. PubMed ID: 24456504
[TBL] [Abstract][Full Text] [Related]
7. Molecular analysis of a recurrent glioblastoma treated with bevacizumab.
Furuta T; Nakada M; Misaki K; Sato Y; Hayashi Y; Nakanuma Y; Hamada J
Brain Tumor Pathol; 2014 Jan; 31(1):32-9. PubMed ID: 23504126
[TBL] [Abstract][Full Text] [Related]
8. Reversible posterior leukoencephalopathy syndrome associated with bevacizumab/doxorubicin regimen.
Bürki F; Badie K; Bartoli P; Bernard P; Montastruc JL; Bagheri H
Br J Clin Pharmacol; 2008 May; 65(5):793-4. PubMed ID: 18279475
[No Abstract] [Full Text] [Related]
9. [Retrospective analysis of 24 recurrent glioblastoma after chemoradiation and treated with nitrosoureas or irinotecan and bevacizumab].
Vauleon E; Mesbah H; Gedouin D; Lecouillard I; Louvel G; Hamlat A; Riffaud L; Carsin B; Quillien V; Audrain O; Lesimple T
Bull Cancer; 2012 Feb; 99(2):121-6. PubMed ID: 22257744
[TBL] [Abstract][Full Text] [Related]
10. Reversible posterior leukoencephalopathy syndrome induced by bevacizumab plus chemotherapy in colorectal cancer.
Wang W; Zhao LR; Lin XQ; Feng F
World J Gastroenterol; 2014 Jun; 20(21):6691-7. PubMed ID: 24914397
[TBL] [Abstract][Full Text] [Related]
11. A review of dose-dense temozolomide alone and in combination with bevacizumab in patients with first relapse of glioblastoma.
Johansson F; Ekman S; Blomquist E; Henriksson R; Bergström S; Bergqvist M
Anticancer Res; 2012 Sep; 32(9):4001-6. PubMed ID: 22993350
[TBL] [Abstract][Full Text] [Related]
12. [An evaluation of fatigue in patients with glioblastoma relapse treated with the combination of irinotecan-bevacizumab].
Dehais C; Souvannavong V; Nguyen BK; Jouniaux-Delbez N; Golmard JL; Tadrist C; Liou A; Delattre JY
Rev Neurol (Paris); 2011 Nov; 167(11):841-6. PubMed ID: 21514945
[TBL] [Abstract][Full Text] [Related]
13. Reversible posterior leukoencephalopathy syndrome and bevacizumab in breast cancer.
Sclafani F; Giuseppe G; Mezynksi J; Collins C; Crown J
J Clin Oncol; 2012 Sep; 30(26):e257-9. PubMed ID: 22649141
[No Abstract] [Full Text] [Related]
14. A meta-analysis of bevacizumab alone and in combination with irinotecan in the treatment of patients with recurrent glioblastoma multiforme.
Zhang G; Huang S; Wang Z
J Clin Neurosci; 2012 Dec; 19(12):1636-40. PubMed ID: 23047061
[TBL] [Abstract][Full Text] [Related]
15. Posterior reversible encephalopathy syndrome associated with deoxycoformycin and alemtuzumab.
Cooksley T; Haji-Michael P
J R Coll Physicians Edinb; 2011 Sep; 41(3):215-7. PubMed ID: 21949916
[TBL] [Abstract][Full Text] [Related]
16. Treatment of children with glioblastoma with conformal radiation, temozolomide, and bevacizumab as adjuncts to surgical resection.
Friedman GK; Spiller SE; Harrison DK; Fiveash JB; Reddy AT
J Pediatr Hematol Oncol; 2013 Apr; 35(3):e123-6. PubMed ID: 23425999
[TBL] [Abstract][Full Text] [Related]
17. Bevacizumab plus irinotecan in recurrent glioblastoma.
Chamberlain MC
J Clin Oncol; 2008 Feb; 26(6):1012-3; author reply 1013. PubMed ID: 18281677
[No Abstract] [Full Text] [Related]
18. Taming glioblastoma by targeting angiogenesis: 3 years later.
Wong ET; Brem S
J Clin Oncol; 2011 Jan; 29(2):124-6. PubMed ID: 21135277
[No Abstract] [Full Text] [Related]
19. Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme.
Vredenburgh JJ; Desjardins A; Kirkpatrick JP; Reardon DA; Peters KB; Herndon JE; Marcello J; Bailey L; Threatt S; Sampson J; Friedman A; Friedman HS
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):58-66. PubMed ID: 21036490
[TBL] [Abstract][Full Text] [Related]
20. Clinical features and outcomes of posterior reversible encephalopathy syndrome following bevacizumab treatment.
Seet RC; Rabinstein AA
QJM; 2012 Jan; 105(1):69-75. PubMed ID: 21865314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
